Khatuna Gabunia

Khatuna Gabunia

Auto-generated profile, based on publicly available information

Khatuna Gabunia

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2024 in Science Immunology
Verified
Journal Article
Closed access
RPRuchi P. Patel
Ruchi P. Patel
GGGuido Ghilardi
Guido Ghilardi
YZYunlin Zhang
Yunlin Zhang
YCYi-Hao Chiang
Yi-Hao Chiang
WXWei Xie
Wei Xie
MRMarco Ruella
Marco Ruella
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.

29 April 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
DSDivanshu Shukla
Divanshu Shukla
KGKhatuna Gabunia
Khatuna Gabunia
SMShannon E. McGettigan
Shannon E. McGettigan
PPPrachi R. Patel
Prachi R. Patel
SCShannon Christensen
Shannon Christensen
JRJames L. Riley
James L. Riley
Patients can develop human anti-mouse immune responses against CD19-specific chimeric antigen receptor (CAR) T cells due to the use of a murine CD19-specific single-chain variable fragment to redirect T cells. We screened a yeast display library to identify an array of fully human CD19 single-chain variable fragment binders and performed a series of studies to select the most promising fully human CAR. We observed significant differences in the ability of CARs employing these CD19 binders to be expressed on the cell surface, induce tonic signaling, redirect T-cell function, mediate tumor killing, recognize lower levels of CD19 antigen, and maintain function upon continuous antigen exposure. From this initial analysis, CAR T cells using two binders (42 and 52) were selected for additional studies. Although CAR T cells using both binders controlled tumor growth well in vivo, we advanced a CAR construct using binder 42 for more advanced preclinical testing because of its greater similarity to binders based on the antibody FMC63, which is the murine antibody underlying four FDA-approved CD19-specific CAR T-cell therapies, and ability to robustly respond to tumors expressing lower levels of CD19. We found that this binder uniquely bound CD19 using distinct contact residues than FMC63 and with ∼40-fold lower affinity. CARs using binder 42 were non-inferior to those using the FMC63 binder in a mouse model of acute lymphoblastic leukemia, indicating that CAR T cells using binder 42 should be considered for clinical use.

16 April 2026 in Blood
Verified
Journal Article
Closed access
JDJoseph S Durgin
Joseph S Durgin
SSShin H Seo
Shin H Seo
SKShadab Kazmi
Shadab Kazmi
BVBakir Valentić
Bakir Valentić
CLChloe Leff
Chloe Leff
SGSaba Ghassemi
Saba Ghassemi
Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment of B-cell malignancies, yet challenges including manufacturing delays, T-cell exhaustion, and limited persistence impede broader clinical success. Here, we report the single day production of non-activated CAR T-cells engineered to secrete interleukin-18 (IL-18), a pro-inflammatory cytokine that enhances T-cell function. These non-activated CART-IL18 cells exhibit robust anti-tumor efficacy across xenograft models of lymphoma, leukemia, and pancreatic cancer. IL-18 expression enhances the functional advantages of naïve-like non-activated CAR T-cells, resulting in improved persistence, metabolic fitness, and resistance to exhaustion. Single-cell transcriptomic analysis revealed upregulation of IL7R, KLF2, and MCL1, alongside suppression of inhibitory checkpoint genes such as PDCD1, TOX, and HAVCR2. Metabolomic profiling demonstrated enhanced mitochondrial bioenergetics, with increased spare respiratory capacity and accumulation of α-ketoglutarate, malate, and spermine. Functional in vitro and in vivo profiling demonstrated enhanced per-cell cytotoxicity and in vivo durability. We complemented these studies with single-cell transcriptomic and metabolomic analyses to define CAR T-cell biological states beyond what is captured by xenograft tumor clearance. This IL-18-enhanced, activation-free CAR T product offers a clinically actionable platform with the potential to reduce vein-to-vein time while improving product potency and persistence, providing a rationale for clinical testing in patients with tumors refractory to standard CAR T.

4 June 2025
Verified
Other
Open access
DSDivanshu Shukla
Divanshu Shukla
KGKhatuna Gabunia
Khatuna Gabunia
SMShannon E. McGettigan
Shannon E. McGettigan
PPPrachi R. Patel
Prachi R. Patel
SCShannon Christensen
Shannon Christensen
JRJames L. Riley
James L. Riley
Supplemental Figure 1: a-b) Primary human T cells stimulated using anti-CD3/28 beads and on the following day were transduced with indicated CARs. Cells were stained with G4S linker antibody (a) and FITC-labeled human CD19 protein (b). c) After 12 days of culture, CAR expression was evaluated using FITC-labeled human CD19 protein.

4 June 2025
Verified
Other
Open access
DSDivanshu Shukla
Divanshu Shukla
KGKhatuna Gabunia
Khatuna Gabunia
SMShannon E. McGettigan
Shannon E. McGettigan
PPPrachi R. Patel
Prachi R. Patel
SCShannon Christensen
Shannon Christensen
JRJames L. Riley
James L. Riley
Supplemental Figure 3: Anti-CD19 control MAbs HIB19 and CB19 were screened on a CD19 alanine-scan mutation library expressed in HEK 293T cells, with binding assayed by flow cytometry. Binding values are shown as a percentage of the antibodies’ binding to the parental CD19 protein (WT) and represent the mean of at least two replicate data points, with error bars showing half of the range (half of the maximum minus minimum value). The mutations highlighted are ones in which binding of 42 scFv was significantly impaired.